Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Paper
  • Published:

Silibinin upregulates the expression of cyclin-dependent kinase inhibitors and causes cell cycle arrest and apoptosis in human colon carcinoma HT-29 cells

Oncogene volume 22, pages 8271–8282 (2003)Cite this article

Abstract

Silymarin, a defined mixture of natural flavonoid, has recently been shown to have potent cancer chemopreventive efficacy against colon carcinogenesis in rat model; however, the mechanism of such efficacy is not elucidated. Here, using pure active agent in silymarin, namely silibinin, we show its antiproliferative and apoptotic effects, and associated molecular alterations in human colon carcinoma HT-29 cells. Silibinin treatment of cells at 50–100 μg/ml doses resulted in a moderate to very strong growth inhibition in a dose- and a time-dependent manner, which was largely due to a G0/G1 arrest in cell cycle progression; higher dose and longer treatment time also caused a G2/M arrest. In mechanistic studies related its effect on cell cycle progression, silibinin treatment resulted in an upregulation of Kip1/p27 and Cip1/p21 protein as well as mRNA levels, and decreased CDK2, CDK4, cyclin E and cyclin D1 protein levels together with an inhibition in CDK2 and CDK4 kinase activities. In other studies, we observed that G2/M arrest by silibinin was associated with a decrease in cdc25C, cdc2/p34 and cyclin B1 protein levels, as well as cdc2/p34 kinase activity. In the studies assessing biological fate of silibinin-treated cells, silibinin-induced cell cycle arrest and growth inhibition were not associated with cellular differentiation, but caused apoptotic death. The quantitative apoptosis analysis showed up to 15% apoptotic cell death after 48 h of silibinin treatment. Interestingly, silibinin-induced apoptosis in HT-29 cells was independent of caspases activation, as all caspases inhibitor did not reverse silibinin-induced apoptosis. This observation was further confirmed by the findings showing a lack in caspases activity increase and caspases and PARP cleavage as well as a lack in cytochrome c release in cytosol following silibinin treatment of HT-29 cells. Additional studies conducted in mice showed that silibinin doses found effective in HT-29 cells are achievable in plasma, which increases the significance of the present findings and their possible translation in in vivo anticancer efficacy of silibinin against colon cancer. Together, these results identify molecular mechanisms of silibinin efficacy as a cell cycle regulator and apoptosis inducer in human colon carcinoma HT-29 cells, and justify further studies to investigate potential usefulness of this nontoxic agent in colon cancer prevention and intervention.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on SpringerLink
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4
Figure 5
Figure 6
Figure 7

Similar content being viewed by others

References

  • Ahmad N, Gali H, Javed S and Agarwal R . (1998). Biochem. Biophys. Res. Commun., 248, 294–301.

  • Bhatia N, Zhao J, Wolf DM and Agarwal R . (1999). Cancer Lett., 147, 77–84.

  • Catzavelos C, Bhattacharya N, Yng YC, Wilson JA, Roncari L, Sandhu C, Shaw P, Yeger H, Morava-Protzner I, Kapusta L, Franssen E, Pritchard KI and Slingerland JM . (1997). Nat. Med., 3, 227–230.

  • Chinni SR, Li Y, Upadhyay S and Koppulu PK . (2001). Oncogene, 20, 2927–2936.

  • Ding QM, Ko TC and Evers BM . (1998). Am. J. Physiol., 275, c1191–c1192.

  • Dhanalakshmi S, Singh RP, Agarwal C and Agarwal R . (2002). Oncogene, 21, 1759–1767.

  • Dulic V, Lees E and Reed SI . (1992). Science (Washington DC), 257, 1958–1961.

  • Esposito V, Baldi A, De Luca A, Groger AM, Loda M, Giordano GG, Caputi M, Baldi F, Pagano M and Giordano A . (1997). Cancer Res., 57, 3381–3385.

  • Fero ML, Randel E, Gurley KE and kemp CJ . (1998). Nature (Lond.), 396, 177–180.

  • Flora K, Hahn M, Rosen H and Benner K . (1998). Am. J. Gastroenterol., 93, 139–143.

  • Gilfix BM and Eckert RL . (1985). J. Biol. Chem., 260, 14026–14029.

  • Grana X and Reddy P . (1995). Oncogene, 11, 211–219.

  • Graves PR, Yu L, Schwarz JK, Gales J, Sausville EA, O'Connor PM and Piwnica-Worms H . (2000). J. Biol. Chem., 275, 5600–5605.

  • Guo Y, Sklar GN, Borkowski A and Kyprianou N . (1997). Clin. Cancer Res., 3, 2269–2274.

  • Gupta RA and DuBois RN . (2001). Nat. Rev. Cancer, 1, 11–21.

  • Hahn VG, Lehmann HD, Kurten M, Uebel H and Vogel G . (1968). Arzneimittelforschung, 18, 698–704.

  • Hanahan D and Weinberg RA . (2000). Cell, 100, 57–70.

  • Hunter T and Pines J . (1994). Cell, 79, 573–582.

  • Jemal A, Thomas A, Murrey T and Thun M . (2002). CA Cancer J. Clin., 52, 23–47.

  • Jordan R, Bradley G and Slingerland JM . (1998). Am. J. Pathol., 152, 585–590.

  • Katiyar SK, Korman NJ, Mukhtar H and Agarwal R . (1997). J. Natl. Cancer Inst., 89, 556–566.

  • Kinzler KW and Vogelstein B . (1996). Cell, 87, 159–170.

  • Kitamura S, Miyazaki Y, Shinomura Y, Kondo S, Kanayama S and Matsuzawa Y . (1999). Jpn. J. Cancer Res., 90, 75–80.

  • Kohno H, Tanaka T, Kawabata K, Hirose Y, Sugie S, Tsuda H and Mori H . (2002). Int. J. Cancer, 101, 461–468.

  • Lahiri-Chatterjee M, Katiyar SK, Mohan RR and Agarwal R . (1999). Cancer Res., 59, 622–632.

  • Lloyd RV, Erickson LA, Jin L, Kulig E, Qian X, Cheville JC and Scheithauer BW . (1999). Am. J. Pathol., 154, 313–323.

  • Lowe SW and Lin AW . (2000). Carcinogenesis, 21, 485–495.

  • Moragoda L, Jaszewski R and Majumdar AP . (2001). Anticancer Res., 21, 873–878.

  • Morgan DO . (1995). Nature (Lond.), 374, 131–134.

  • Mori M, Mimori K, Shiraishi T, Tanaka S, Ueo H, Sugimachi K and Akiyoshi T . (1997). Nat. Med., 3, 593.

  • Polyak K, Kato J-Y, Soloman MJ, Sherr CJ, Massague J, Roberts JM and Koff A . (1994a). Genes Dev., 8, 9–22.

  • Polyak K, Lee MH, Erdjument-Bromage H, Koff A, Roberts JM, Tempst P and Massague J . (1994b). Cell, 78, 59–66.

  • Samowitz WS, Curtin K, Ma KN, Edwards S, Schaffer D, Leppert MF and Slattery ML . (2002). Int. J. Cancer, 99, 597–602.

  • Sebolt-Leopold JS, Dudley DT, Herrera R, Becelaere KV, Wiland A, Gowan RC, Tecle H, Barrett SD, Bridges A, Przybranowski S, Leopold WR and Saltiel AR . (1999). Nat. Med., 5, 810–816.

  • Sherr CJ . (1994). Cell, 79, 551–555.

  • Sherr CJ and Roberts JM . (1999). Genes Dev., 13, 1501–1512.

  • Singh RP, Dhanalakshmi S, Tyagi AK, Chan DCF, Agarwal C and Agarwal R . (2002a). Cancer Res., 62, 3063–3069.

  • Singh RP, Tyagi AK, Zhao J and Agarwal R . (2002b). Carcinogenesis, 23, 499–510.

  • Taylor WR and Stark GR . (2001). Oncogene, 20, 1803–1815.

  • Thompson CB . (1995). Science, 267, 1456–1462.

  • Torrance CJ, Jackson PE, Montgomery E, Kinzler KW, Vogelstein V, Wissner A, Nunes M, Frost P and Discafani CM . (2000). Nat. Med., 6, 1024–1028.

  • Tsai LH, Lees E, Faha B, Harlow E and Riabowol K . (1993). Oncogene, 8, 1593–1602.

  • Tyagi AK, Singh RP, Agarwal C, Chan DCF and Agarwal R . (2002). Clin. Cancer Res., 8, 3512–3519.

  • Vogel G, Trost W and Braatz R . (1975). Arzneimittelforschung, 25, 82–89.

  • Wellington K and Jarvis B . (2001). BioDrugs, 15, 465–489.

  • Xiong Y, Hannon GJ, Zhang H, Casso D, Kobayashi R and Beach D . (1993). Nature, 366, 701–704.

  • Zi X and Agarwal R . (1999a). Proc. Natl. Acad. Sci. USA, 96, 7490–7495.

  • Zi X and Agarwal R . (1999b). Biochem. Biophys. Res. Commun., 263, 528–536.

  • Zi X, Feyes DK and Agarwal R . (1998a). Clin. Cancer Res., 4, 1055–1064.

  • Zi X, Grasso AW, Kung H and Agarwal R . (1998b). Cancer Res., 58, 1920–1929.

  • Zi X, Mukhtar H and Agarwal R . (1997). Biochem. Biophys. Res. Commun., 239, 334–339.

Download references

Acknowledgements

This work was supported in part by USPHS Grants CA64514, CA91883 and CA99079.

Author information

Authors and Affiliations

  1. Department of Pharmaceutical Sciences, School of Pharmacy, University of Colorado Health Sciences Center, Denver, 80262, CO, USA

    Chapla Agarwal, Rana P Singh, Sivanandhan Dhanalakshmi, Anil K Tyagi & Rajesh Agarwal

  2. Department of Biochemistry and Molecular Genetics, University of Colorado Health Sciences Center, Denver, 80262, CO, USA

    Marianne Tecklenburg & Robert A Sclafani

  3. University of Colorado Cancer Center, University of Colorado Health Sciences Center, Denver, 80262, CO, USA

    Marianne Tecklenburg, Robert A Sclafani & Rajesh Agarwal

Authors
  1. Chapla Agarwal
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Rana P Singh
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Sivanandhan Dhanalakshmi
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Anil K Tyagi
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Marianne Tecklenburg
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Robert A Sclafani
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Rajesh Agarwal
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Rajesh Agarwal.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Agarwal, C., Singh, R., Dhanalakshmi, S. et al. Silibinin upregulates the expression of cyclin-dependent kinase inhibitors and causes cell cycle arrest and apoptosis in human colon carcinoma HT-29 cells. Oncogene 22, 8271–8282 (2003). https://doi.org/10.1038/sj.onc.1207158

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.onc.1207158

Keywords

Search

Advanced search

Quick links